238 related articles for article (PubMed ID: 31078244)
1. The Era of Anti-Tumor Necrosis Factor Is Over. What Do We Know, What Don't We Know, and What Do We Yearn to Know?
Dwadasi S; Israel A; Rubin DT
Gastrointest Endosc Clin N Am; 2019 Jul; 29(3):405-419. PubMed ID: 31078244
[No Abstract] [Full Text] [Related]
2. Clinical and scientific aspects related to biosimilars in inflammatory bowel diseases (IBD): position document of the Belgian IBD Research & Development Group (BIRD).
Vermeire S; Louis E; Dewit O; Franchimont D; Moreels T; Ferrante M; Rahier JF; Van Hootegem P; De Vos M; Mana F; Baert F;
Acta Gastroenterol Belg; 2015; 78(1):26-9. PubMed ID: 26118575
[No Abstract] [Full Text] [Related]
3. New Zealand Society of Gastroenterology Guidelines for the Management of Refractory Ulcerative Colitis.
Eliadou E; Day AS; Thompson-Fawcett MW; Gearry RB; Rowbotham DS; Walmsley R; Schultz M; Inns SJ; ;
N Z Med J; 2015 Oct; 128(1423):63-76. PubMed ID: 26645757
[TBL] [Abstract][Full Text] [Related]
4. The immunogenicity of biosimilar infliximab: can we extrapolate the data across indications?
Ben-Horin S; Heap GA; Ahmad T; Kim H; Kwon T; Chowers Y
Expert Rev Gastroenterol Hepatol; 2015; 9 Suppl 1():27-34. PubMed ID: 26395532
[TBL] [Abstract][Full Text] [Related]
5. An update on biosimilar drugs for inflammatory bowel disease.
Schreiber S
Expert Rev Gastroenterol Hepatol; 2015; 9 Suppl 1():1-3. PubMed ID: 26395529
[TBL] [Abstract][Full Text] [Related]
6. Biosimilar infliximab for inflammatory bowel disease: from concepts to clinical practice. Case study illustrated with CT-P13.
Schreiber S; Panés J; Kwon B; Hong S; Peyrin-Biroulet L
Expert Rev Gastroenterol Hepatol; 2015; 9 Suppl 1():5-15. PubMed ID: 26395530
[TBL] [Abstract][Full Text] [Related]
7. Ulcerative Colitis.
Sonnenberg E; Siegmund B
Digestion; 2016; 94(4):181-185. PubMed ID: 27931025
[TBL] [Abstract][Full Text] [Related]
8. The scientific and regulatory rationale for indication extrapolation: a case study based on the infliximab biosimilar CT-P13.
Reinisch W; Louis E; Danese S
Expert Rev Gastroenterol Hepatol; 2015; 9 Suppl 1():17-26. PubMed ID: 26395531
[TBL] [Abstract][Full Text] [Related]
9. [Perspectives in inflammatory bowel diseases treatment].
Jalocha L; Wojtuń S; Dyrla P; Błaszak A; Wojtkowiak M; Zyśko B; Stelmaszuk T; Gil J
Pol Merkur Lekarski; 2009 May; 26(155):556-8. PubMed ID: 19606725
[TBL] [Abstract][Full Text] [Related]
10. Advanced therapies in inflammatory bowel disease: Special considerations.
Williams AJ
J Gastroenterol Hepatol; 2021 Apr; 36 Suppl 1():22-24. PubMed ID: 33817851
[No Abstract] [Full Text] [Related]
11. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics.
Menter A; Strober BE; Kaplan DH; Kivelevitch D; Prater EF; Stoff B; Armstrong AW; Connor C; Cordoro KM; Davis DMR; Elewski BE; Gelfand JM; Gordon KB; Gottlieb AB; Kavanaugh A; Kiselica M; Korman NJ; Kroshinsky D; Lebwohl M; Leonardi CL; Lichten J; Lim HW; Mehta NN; Paller AS; Parra SL; Pathy AL; Rupani RN; Siegel M; Wong EB; Wu JJ; Hariharan V; Elmets CA
J Am Acad Dermatol; 2019 Apr; 80(4):1029-1072. PubMed ID: 30772098
[TBL] [Abstract][Full Text] [Related]
12. Successful Treatment of Pyoderma Gangrenosum with Concomitant Tofacitinib and Infliximab.
Gregory MH; Ciorba MA; Deepak P; Christophi GP
Inflamm Bowel Dis; 2019 Jun; 25(7):e87-e88. PubMed ID: 30753456
[No Abstract] [Full Text] [Related]
13. Efficacy of tofacitinib treatment in ulcerative colitis.
Panés J; Gisbert JP
Gastroenterol Hepatol; 2019; 42(6):403-412. PubMed ID: 31101342
[TBL] [Abstract][Full Text] [Related]
14. Clinical impact of immunomonitoring in the treatment of inflammatory bowel disease.
Tighe D; McNamara D
World J Gastroenterol; 2017 Jan; 23(3):414-425. PubMed ID: 28210077
[TBL] [Abstract][Full Text] [Related]
15. Understanding the complications of anti-tumor necrosis factor therapy in East Asian patients with inflammatory bowel disease.
Cheon JH
J Gastroenterol Hepatol; 2017 Apr; 32(4):769-777. PubMed ID: 27723166
[TBL] [Abstract][Full Text] [Related]
16. Risks and benefits of combining immunosuppressives and biological agents in inflammatory bowel disease: is the synergy worth the risk?
Hanauer SB
Gut; 2007 Sep; 56(9):1181-3. PubMed ID: 17698862
[TBL] [Abstract][Full Text] [Related]
17. Anti-TNF-α agents and serum lipids in inflammatory bowel diseases.
Kalkan Ç; Karakaya F; Törüner M; Çetinkaya H; Soykan I
Clin Res Hepatol Gastroenterol; 2016 Sep; 40(4):e46-7. PubMed ID: 26852393
[No Abstract] [Full Text] [Related]
18. Long-term Efficacy, Safety, and Immunogenicity of Biosimilar Infliximab After One Year in a Prospective Nationwide Cohort.
Gonczi L; Gecse KB; Vegh Z; Kurti Z; Rutka M; Farkas K; Golovics PA; Lovasz BD; Banai J; Bene L; Gasztonyi B; Kristof T; Lakatos L; Miheller P; Nagy F; Palatka K; Papp M; Patai A; Salamon A; Szamosi T; Szepes Z; Toth GT; Vincze A; Szalay B; Molnar T; Lakatos PL
Inflamm Bowel Dis; 2017 Nov; 23(11):1908-1915. PubMed ID: 28922253
[TBL] [Abstract][Full Text] [Related]
19. A Review on the Use of Anti-TNF in Children and Adolescents with Inflammatory Bowel Disease.
Aardoom MA; Veereman G; de Ridder L
Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31126015
[TBL] [Abstract][Full Text] [Related]
20. An economic evaluation of tofacitinib for the treatment of moderately-to-severely active ulcerative colitis: modeling the cost of treatment strategies in the United States.
Milev S; DiBonaventura MD; Quon P; Wern Goh J; Bourret J; Peeples-Lamirande K; Soonasra A; Cappelleri JC; Quirk D
J Med Econ; 2019 Sep; 22(9):859-868. PubMed ID: 31012362
[No Abstract] [Full Text] [Related]
[Next] [New Search]
